Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license
IFNL3 · rs8103142
Stands on its own. Nothing else here links to this position yet — but the page above is the point: what the research found, what each genotype means, and where it came from, in language you can read. Links to conditions, drugs and the senses appear automatically if we write them.
Strength of the evidence
Its strongest genetic-study result is p = 10−12, with 2 associations in the GWAS Catalog.
4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.
What the study found
Who was studied 977 African American or Afro-Caribbean cases, 120,676 African American or Afro-Caribbean controls, 2,852 European ancestry cases, 447,587 European ancestry controls, 630 Hispanic or Latin American cases, 59,146 Hispanic or Latin American controls.
The effect Each copy of the T allele shifted the measure 0.16 lower (95% confidence interval 0.12-0.2); p = 3 × 10−12.
How common The T allele had a frequency of about 62% in the people studied.
Where it sits Chromosome 19, band 19q13.2 — a missense change in IFNL3.
What ClinVar records
Classification
Likely benign; criteria provided, multiple submitters, no conflicts (2 of 4 stars, 2 submitters), last evaluated 2018-03-09.
ClinVar record 511091 NM_172139.4(IFNL3):c.209A>G (p.Lys70Arg)
Change history MyGeneLog™ keeps a copy of every weekly release from 2026-10-19 and compares them. This position's classification has not changed since.
What this is ClinVar's aggregate record for this position (as of its 2026-11-01 release), not a result about you. A classification describes the variant against the condition named, as laboratories submitted it. Whether a person carries this variant, and what that would mean for them, is a question for a clinical test and a genetic counsellor.
How common each version is
CT
C 5.9% · T 94.1%
C 6.2% · T 93.8%
C 10.3% · T 89.7%
C 39.7% · T 60.3%
C 36.5% · T 63.5%
C 41.8% · T 58.2%
By ancestry gnomAD
C 7.2% · T 92.8%
C 31.8% · T 68.2%
C 62.9% · T 37.1%
C 23.1% · T 76.9%
C 38.2% · T 61.8%
C 39.1% · T 60.9%
C 24.0% · T 76.0%
C 42.9% · T 57.1%
The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study. The ancestry rows are gnomAD's own groups (via Ensembl), as the survey defines them, not races.
Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license
Malignant neoplasm of liver, primary (PheCode 155.1) (rs8103142). MyGeneLog™. https://www.mygenelog.com/variants/rs8103142